Abstract:Adenosine triphosphate (ATP)-binding cassette (ABC) transporters play a key role in the development of multidrug resistance (MDR) in cancer cells. P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are important proteins in this superfamily which are widely expressed on the membranes of multidrug resistance (MDR) cancer cells. Besides, upregulation of cellular autophagic responses is considered a contributing factor for MDR in cancer cells. We designed a liposome system co-encapsulating a chemotherapeutic drug (doxorubicin hydrochloride, DOX) and a typical autophagy inhibitior (chloroquine phosphate, CQ) at a weight ratio of 1:2 and investigated its drug resistance reversal mechanism. MTT assay showed that the IC50 of DOX/CQ co-encapsulated liposome in DOX-resistant human breast cancer cells (MCF7/ADR) was 4.7 +/- 0.2 mu M, 5.7-fold less than that of free DOX (26.9 +/- 1.9 mu M), whereas it was 19.5-fold in doxorubicin-resistant human acute myelocytic leukemia cancer cells (HL60/ADR) (DOX/CQ co-encapsulated liposome 1.2 +/- 0.1 mu M, free DOX 23.4 +/- 2.8 mu M). The cellular uptake of DOX increased upon addition of free CQ, indicating that CQ may interact with P-gp and MRP1; however, the expressions of P-gp and MRP1 remained unchanged. In contrast, the expression of the autophagy-related protein LC3-II increased remarkably. Therefore, the mechanism of MDR reversal may be closely related to autophagic inhibition. Evaluation of antitumor activity was achieved in an MCF-7/ADR multicellular tumor spheroid model and transgenic zebrafish model. DOX/CQ co-encapsulated liposome exerted a better anti-tumor effect in both models than that of liposomal DOX or DOX alone. These findings suggest that encapsulating CQ with DOX in liposomes significantly improves the sensitivity of DOX in DOX-resistant cancer cells.

Mechanism Study of Doxorubicin-schisandrin B Co-delivery Liposomes to Overcome Multidrug Resistance

Co-Delivery of Doxorubicin and Schisandrin B by Liposome to Overcome Multidrug Resistance

Molecular Mechanism Study of Chemosensitization of Doxorubicin-Resistant Human Myelogenous Leukemia Cells Induced by a Composite Polymer Micelle

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Overcoming multidrug resistance by co-delivering of MDR1 targeting siRNA and doxorubicin using EphA10-mediated pH-sensitive lipoplexes：In vitro and in vivo evaluation.

Mesoporous Silica Nanoparticles Loading Doxorubicin Reverse Multidrug Resistance: Performance And Mechanism

Sensitization Of Multidrug-Resistant Malignant Cells By Liposomes Co-Encapsulating Doxorubicin And Chloroquine Through Autophagic Inhibition

Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic

Co-delivery of Doxorubicin and P-gp Inhibitor by a Reduction-Sensitive Liposome to Overcome Multidrug Resistance, Enhance Anti-Tumor Efficiency and Reduce Toxicity

Sequential Therapy with Redox-Responsive Glucolipid Nanocarrier Separately Delivering Sirna and Doxorubicin to Overcome Multidrug Resistance.

Overcoming multidrug resistance by intracellular drug release and inhibiting p-glycoprotein efflux in breast cancer

Increasing The Cytotoxicity Of Doxorubicin In Breast Cancer Mcf-7 Cells With Multidrug Resistance Using A Mesoporous Silica Nanoparticle Drug Delivery System

The combination therapy of doxorubicin and quercetin on multidrug resistant breast cancer and their sequential delivery by reduction-sensitive hyaluronic acid-based conjugate / D-α-tocopheryl polyethylene glycol 1000 succinate mixed micelles.

Enhanced Effect of Ph-Sensitive Mixed Copolymer Micelles for Overcoming Multidrug Resistance of Doxorubicin.

Co-Delivery of Doxorubicin and Sirna with Reduction and Ph Dually Sensitive Nanocarrier for Synergistic Cancer Therapy

Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition

Co-delivery of Doxorubicin and Imatinib by Ph Sensitive Cleavable PEGylated Nanoliposomes with Folate-Mediated Targeting to Overcome Multidrug Resistance.

Reversal of Multidrug Resistance Phenotype in Human Breast Cancer Cells Using Doxorubicin-Liposome–microbubble Complexes Assisted by Ultrasound

Co-delivery Nanoparticles of Doxorubicin and Chloroquine for Improving the Anti-Cancer Effect in Vitro

Integrin Receptor-Mediated Strategy for Tumor Targeting Delivery of siRNA and Doxorubicin

Liposome-Based Intracellular Kinetics of Doxorubicin in K562/Dox Cells